- Exchange: Oslo
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Snapshot for Algeta ASA (ALGETA)
| Open: | 221.000 | Day's Range: | 220.600 - 224.500 | Volume: | 53,016 |
|---|---|---|---|---|---|
| Previous Close: | 223.900 | 52wk Range: | 133.000 - 245.400 | 1-Yr Rtn: | +61.98% |
Key Statistics for ALGETA
| Current P/E Ratio (ttm) | 54.7645 |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. OBX | 4.0913 |
| Earnings Per Share (NOK) (ttm) | 4.0994 |
| Est. EPS (NOK) (12/2013) | -0.5820 |
| Est. PEG Ratio | - |
| Market Cap (M NOK) | 9,826.74 |
| Shares Outstanding (M) | 43.77 |
| 30 Day Average Volume | 201,482 |
| Price/Book (mrq) | 12.6456 |
| Price/Sale (ttm) | 15.2454 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/28/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ALGETA
Company Profile & Key Executives for ALGETA
Algeta ASA operates in the pharmaceutical industry. The Company develops targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Algeta's compound Alpharadin is designed to treat bone metastases.
| John Edward BerrimanDeputy Chairman | Andrew Martin KayPresident/CEO |
| Oystein SougChief Financial Officer | Roger HarrisonChief Business Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ALGETA News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page